ID   BT-474
AC   CVCL_0179
SY   Bt-474; BT474
DR   BTO; BTO:0001932
DR   CLO; CLO_0002042
DR   EFO; EFO_0001093
DR   MCCL; MCC:0000070
DR   CLDB; cl497
DR   CLDB; cl498
DR   CLDB; cl4997
DR   AddexBio; C0006012/4902
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ArrayExpress; E-TABM-157
DR   ArrayExpress; E-TABM-244
DR   ATCC; CRL-7913
DR   ATCC; HTB-20
DR   BCRC; 60359
DR   BCRJ; 0353
DR   BioSample; SAMN01821539
DR   BioSample; SAMN01821618
DR   BioSample; SAMN03473029
DR   BioSample; SAMN10988308
DR   BioSamples; SAMEA3516847
DR   BioSamples; SAMEA3516848
DR   BioSamples; SAMEA3516849
DR   cancercelllines; CVCL_0179
DR   CCRID; 1101HUM-PUMC000129
DR   CCRID; 1102HUM-NIFDC00023
DR   CCRID; 3101HUMTCHu143
DR   CCRID; 4201HUM-CCTCC00636
DR   Cell_Model_Passport; SIDM00963
DR   ChEMBL-Cells; CHEMBL3307636
DR   ChEMBL-Targets; CHEMBL614529
DR   CLS; 300131
DR   Cosmic; 687464
DR   Cosmic; 871138
DR   Cosmic; 904351
DR   Cosmic; 923058
DR   Cosmic; 934520
DR   Cosmic; 946359
DR   Cosmic; 970088
DR   Cosmic; 979721
DR   Cosmic; 1000122
DR   Cosmic; 1017168
DR   Cosmic; 1018460
DR   Cosmic; 1046934
DR   Cosmic; 1047699
DR   Cosmic; 1071903
DR   Cosmic; 1129654
DR   Cosmic; 1136353
DR   Cosmic; 1176605
DR   Cosmic; 1287890
DR   Cosmic; 1289383
DR   Cosmic; 1308996
DR   Cosmic; 1434947
DR   Cosmic; 1523771
DR   Cosmic; 1603191
DR   Cosmic; 1609475
DR   Cosmic; 1945863
DR   Cosmic; 2165003
DR   Cosmic; 2301523
DR   Cosmic; 2318376
DR   Cosmic; 2361356
DR   Cosmic-CLP; 946359
DR   DepMap; ACH-000927
DR   DSMZ; ACC-64
DR   DSMZCellDive; ACC-64
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   EGA; EGAS00001002554
DR   GDSC; 946359
DR   GEO; GSM1716
DR   GEO; GSM1725
DR   GEO; GSM69198
DR   GEO; GSM73557
DR   GEO; GSM73702
DR   GEO; GSM115110
DR   GEO; GSM147888
DR   GEO; GSM147957
DR   GEO; GSM149981
DR   GEO; GSM149989
DR   GEO; GSM149997
DR   GEO; GSM155210
DR   GEO; GSM184392
DR   GEO; GSM184393
DR   GEO; GSM213707
DR   GEO; GSM213717
DR   GEO; GSM213718
DR   GEO; GSM213719
DR   GEO; GSM213737
DR   GEO; GSM213740
DR   GEO; GSM213743
DR   GEO; GSM213745
DR   GEO; GSM217615
DR   GEO; GSM274657
DR   GEO; GSM276780
DR   GEO; GSM320173
DR   GEO; GSM344341
DR   GEO; GSM344391
DR   GEO; GSM350504
DR   GEO; GSM388211
DR   GEO; GSM421861
DR   GEO; GSM533397
DR   GEO; GSM533412
DR   GEO; GSM590105
DR   GEO; GSM679677
DR   GEO; GSM679678
DR   GEO; GSM679679
DR   GEO; GSM679680
DR   GEO; GSM679681
DR   GEO; GSM679682
DR   GEO; GSM679683
DR   GEO; GSM679684
DR   GEO; GSM679685
DR   GEO; GSM679686
DR   GEO; GSM679687
DR   GEO; GSM679688
DR   GEO; GSM679689
DR   GEO; GSM679690
DR   GEO; GSM679691
DR   GEO; GSM783958
DR   GEO; GSM799168
DR   GEO; GSM799169
DR   GEO; GSM799170
DR   GEO; GSM799171
DR   GEO; GSM799172
DR   GEO; GSM799173
DR   GEO; GSM847198
DR   GEO; GSM847453
DR   GEO; GSM843476
DR   GEO; GSM886892
DR   GEO; GSM887957
DR   GEO; GSM903063
DR   GEO; GSM903064
DR   GEO; GSM903065
DR   GEO; GSM903066
DR   GEO; GSM903067
DR   GEO; GSM903068
DR   GEO; GSM903069
DR   GEO; GSM967821
DR   GEO; GSM1008891
DR   GEO; GSM1053692
DR   GEO; GSM1172941
DR   GEO; GSM1172853
DR   GEO; GSM1214587
DR   GEO; GSM1238128
DR   GEO; GSM1264068
DR   GEO; GSM1264073
DR   GEO; GSM1264110
DR   GEO; GSM1264115
DR   GEO; GSM1374408
DR   GEO; GSM1374409
DR   GEO; GSM1374410
DR   GEO; GSM1401649
DR   GEO; GSM1669630
DR   GEO; GSM2176271
DR   GEO; GSM2176272
DR   IARC_TP53; 4
DR   IBRC; C10140
DR   ICLC; HTL00008
DR   IGRhCellID; BT474
DR   KCB; KCB 2011115YJ
DR   KCLB; 60062
DR   LiGeA; CCLE_516
DR   LINCS_HMS; 50106
DR   LINCS_LDP; LCL-1308
DR   NCBI_Iran; C435
DR   PharmacoDB; BT474_109_2019
DR   PRIDE; PXD002281
DR   PRIDE; PXD002635
DR   PRIDE; PXD004357
DR   PRIDE; PXD005390
DR   PRIDE; PXD008222
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_0179
DR   PubChem_Cell_line; CVCL_0179
DR   TOKU-E; 694
DR   Wikidata; Q54798460
RX   CelloPub=CLPUB00423;
RX   DOI=10.1007/978-1-4757-0019-0_7;
RX   DOI=10.1016/B978-0-12-333530-2.50009-5;
RX   PubMed=94035;
RX   PubMed=212572;
RX   PubMed=1961733;
RX   PubMed=6582512;
RX   PubMed=7842014;
RX   PubMed=9671407;
RX   PubMed=10862037;
RX   PubMed=10969801;
RX   PubMed=11687795;
RX   PubMed=12353263;
RX   PubMed=12800145;
RX   PubMed=16397213;
RX   PubMed=16142302;
RX   PubMed=16195238;
RX   PubMed=16417655;
RX   PubMed=16541312;
RX   PubMed=17157791;
RX   PubMed=17334996;
RX   PubMed=18386134;
RX   PubMed=18516279;
RX   PubMed=19582160;
RX   PubMed=19593635;
RX   PubMed=19671800;
RX   PubMed=19727395;
RX   PubMed=20070913;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=21247443;
RX   PubMed=22460905;
RX   PubMed=22585861;
RX   PubMed=23151021;
RX   PubMed=23601657;
RX   PubMed=23671654;
RX   PubMed=24094812;
RX   PubMed=24162158;
RX   PubMed=24176112;
RX   PubMed=24389870;
RX   PubMed=24456987;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=25892236;
RX   PubMed=25960936;
RX   PubMed=25984343;
RX   PubMed=26218769;
RX   PubMed=26589293;
RX   PubMed=26865974;
RX   PubMed=27362937;
RX   PubMed=27378269;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=28287265;
RX   PubMed=28889351;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=32942617;
RX   PubMed=35839778;
WW   http://dpsc.ccbr.utoronto.ca/cancer/get_cellline.pl?cellline=BT-474
WW   https://lincs.hms.harvard.edu/resources/reagents/icbp43/
WW   https://www.synapse.org/#!Synapse:syn2346643/wiki/62255
WW   https://tcpaportal.org/mclp/
CC   Part of: AKT genetic alteration cell panel (ATCC TCP-1029).
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: EGFR genetic alteration cell panel (ATCC TCP-1027).
CC   Part of: ERK genetic alteration cell panel (ATCC TCP-1033).
CC   Part of: GrayJW breast cancer cell line panel.
CC   Part of: ICBP43 breast cancer cell line panel.
CC   Part of: KuDOS 95 cell line panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).
CC   Population: Caucasian.
CC   Doubling time: 3.5 days (PubMed=9671407); 78 hours (PubMed=25984343); 45.8 hours (PubMed=24389870); ~60-80 hours (CLS=300131); ~100 hours (DSMZ=ACC-64); 92.49 hours (GrayJW panel).
CC   HLA typing: A*29:02; B*07:02; C*07:02,16:01; DQB1*03:04,06:02; DRB1*15:01,15:01 (PubMed=25960936).
CC   HLA typing: A*02:46,29:02; B*07:02,35:08; C*07:02,16:01; DQB1*03:02,06:02; DRB1*04:05,15:01 (PubMed=26589293).
CC   HLA typing: A*01:01:01,05:02:01; B*07:02:01,20:03:01; C*07:02:01,16:01:01; DPB1*04:01:01G,05:01:01G; DQA1*01:02:01,03:03:01; DQB1*06:02:01; DRB1*04:01,15:01 (CLS=300131).
CC   Microsatellite instability: Stable (MSS) (PubMed=23671654; Sanger).
CC   Sequence variation: Gene fusion; HGNC; 24618; AHCTF1 + HGNC; 736; NAAA; Name(s)=AHCTF1-NAAA (PubMed=26865974).
CC   Sequence variation: Gene fusion; HGNC; 7609; MYO9B + HGNC; 9764; RAB22A; Name(s)=RAB22A-MYO9B (PubMed=21247443; PubMed=26865974).
CC   Sequence variation: Gene fusion; HGNC; 16173; DOK5 + HGNC; 17579; STARD3; Name(s)=STARD3-DOK5 (PubMed=21247443; PubMed=26865974).
CC   Sequence variation: Gene fusion; HGNC; 16651; MRPL45 + HGNC; 16181; TRPC4AP; Name(s)=TRPC4AP-MRPL45 (PubMed=26865974).
CC   Sequence variation: Gene fusion; HGNC; 13178; IKZF3 + HGNC; 12649; VAPB; Name(s)=VAPB-IKZF3 (PubMed=21247443; PubMed=26865974).
CC   Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ser3094Ter (c.9281C>A); ClinVar=VCV000188440; Zygosity=Heterozygous (PubMed=26865974; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 11621; HNF1A; Simple; p.Gln495Ter (c.1483C>T); ClinVar=VCV000586785; Zygosity=Heterozygous (PubMed=26865974; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 6871; MAPK1; Simple; p.His61Gln (c.183C>G); Zygosity=Heterozygous (PubMed=26865974; ATCC; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Lys111Asn (c.333G>C); ClinVar=VCV000376483; Zygosity=Heterozygous (PubMed=19593635; PubMed=26865974; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Homozygous (PubMed=1961733; PubMed=16541312; PubMed=26865974; PubMed=28889351; ATCC; Cosmic-CLP; DepMap).
CC   Omics: Array-based CGH.
CC   Omics: CNV analysis.
CC   Omics: Deep exome analysis.
CC   Omics: Deep phosphoproteome analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Genome sequenced.
CC   Omics: Glycoproteome analysis by proteomics.
CC   Omics: Metabolome analysis.
CC   Omics: miRNA expression profiling.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: shRNA library screening.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0.6%; Native American=0%; East Asian, North=2.47%; East Asian, South=0%; South Asian=0%; European, North=70.19%; European, South=26.74% (PubMed=30894373).
CC   Anecdotal: Used in a study utilising the fruit fly's olfactory system to detect cancer cells (PubMed=24389870).
CC   Discontinued: ATCC; CRL-7913; true.
CC   Derived from site: In situ; Breast; UBERON=UBERON_0000310.
ST   Source(s): AddexBio; ATCC; CCRID; CLS; Cosmic-CLP; DSMZ; Genomics_Center_BCF_Technion; KCLB; PubMed=25877200; PubMed=28889351
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 11
ST   D16S539: 9,11
ST   D18S51: 13,18
ST   D19S433: 14,17
ST   D21S11: 28,32.2
ST   D2S1338: 19
ST   D3S1358: 17
ST   D5S818: 11,13
ST   D7S820: 9,12
ST   D8S1179: 10,12
ST   FGA: 22,25
ST   Penta D: 9,14
ST   Penta E: 5
ST   TH01: 7
ST   TPOX: 8
ST   vWA: 15,16
DI   NCIt; C4194; Invasive breast carcinoma of no special type
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   60Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 44
//
RX   CelloPub=CLPUB00423;
RA   Morrison B.J.;
RT   "Breast cancer stem cells: tumourspheres and implications for therapy.";
RL   Thesis PhD (2010), Griffith University, Australia.
//
RX   DOI=10.1007/978-1-4757-0019-0_7;
RA   Lasfargues E.Y., Coutinho W.G.;
RT   "Human breast tumor cells in culture; new concepts in mammary
RT   carcinogenesis.";
RL   (In) New frontiers in mammary pathology; Hollmann K.H., de Brux J., Verley J.M. (eds.); pp.117-143; Plenum Press; New York (1981).
//
RX   DOI=10.1016/B978-0-12-333530-2.50009-5;
RA   Leibovitz A.;
RT   "Cell lines from human breast.";
RL   (In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.161-184; Academic Press; New York (1994).
//
RX   PubMed=94035; DOI=10.1007/BF02618252;
RA   Lasfargues E.Y., Coutinho W.G., Dion A.S.;
RT   "A human breast tumor cell line (BT-474) that supports mouse mammary
RT   tumonr virus replication.";
RL   In Vitro 15:723-729(1979).
//
RX   PubMed=212572; DOI=10.1093/jnci/61.4.967;
RA   Lasfargues E.Y., Coutinho W.G., Redfield E.S.;
RT   "Isolation of two human tumor epithelial cell lines from solid breast
RT   carcinomas.";
RL   J. Natl. Cancer Inst. 61:967-978(1978).
//
RX   PubMed=1961733; DOI=10.1073/pnas.88.23.10657;
RA   Runnebaum I.B., Nagarajan M., Bowman M., Soto D., Sukumar S.;
RT   "Mutations in p53 as potential molecular markers for human breast
RT   cancer.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:10657-10661(1991).
//
RX   PubMed=6582512; DOI=10.1073/pnas.81.2.568;
RA   Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.;
RT   "Cell surface antigens of human ovarian and endometrial carcinoma
RT   defined by mouse monoclonal antibodies.";
RL   Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984).
//
RX   PubMed=7842014; DOI=10.1038/ng1094-155;
RA   Guan X.-Y., Meltzer P.S., Dalton W.S., Trent J.M.;
RT   "Identification of cryptic sites of DNA sequence amplification in
RT   human breast cancer by chromosome microdissection.";
RL   Nat. Genet. 8:155-161(1994).
//
RX   PubMed=9671407; DOI=10.1038/sj.onc.1201814;
RA   Sweeney K.J., Swarbrick A., Sutherland R.L., Musgrove E.A.;
RT   "Lack of relationship between CDK activity and G1 cyclin expression in
RT   breast cancer cells.";
RL   Oncogene 16:2865-2878(1998).
//
RX   PubMed=10862037; DOI=10.1002/1098-2264(200007)28:3<308::AID-GCC9>3.0.CO;2-B;
RA   Kytola S., Rummukainen J., Nordgren A., Karhu R., Farnebo F.,
RA   Isola J., Larsson C.;
RT   "Chromosomal alterations in 15 breast cancer cell lines by comparative
RT   genomic hybridization and spectral karyotyping.";
RL   Genes Chromosomes Cancer 28:308-317(2000).
//
RX   PubMed=10969801;
RA   Forozan F., Mahlamaki E.H., Monni O., Chen Y.-D., Veldman R., Jiang Y.,
RA   Gooden G.C., Ethier S.P., Kallioniemi A., Kallioniemi O.-P.;
RT   "Comparative genomic hybridization analysis of 38 breast cancer cell
RT   lines: a basis for interpreting complementary DNA microarray data.";
RL   Cancer Res. 60:4519-4525(2000).
//
RX   PubMed=11687795; DOI=10.1038/ng754;
RA   Snijders A.M., Nowak N.J., Segraves R., Blackwood S., Brown N.,
RA   Conroy J., Hamilton G., Hindle A.K., Huey B., Kimura K., Law S.,
RA   Myambo K., Palmer J., Ylstra B., Yue J.P., Gray J.W., Jain A.N.,
RA   Pinkel D., Albertson D.G.;
RT   "Assembly of microarrays for genome-wide measurement of DNA copy
RT   number.";
RL   Nat. Genet. 29:263-264(2001).
//
RX   PubMed=12353263; DOI=10.1002/gcc.10107;
RA   Popovici C., Basset C., Bertucci F., Orsetti B., Adelaide J.,
RA   Mozziconacci M.-J., Conte N., Murati A., Ginestier C.,
RA   Charafe-Jauffret E., Ethier S.P., Lafage-Pochitaloff M., Theillet C.,
RA   Birnbaum D., Chaffanet M.;
RT   "Reciprocal translocations in breast tumor cell lines: cloning of a
RT   t(3;20) that targets the FHIT gene.";
RL   Genes Chromosomes Cancer 35:204-218(2002).
//
RX   PubMed=12800145; DOI=10.1002/gcc.10218;
RA   Adelaide J., Huang H.-E., Murati A., Alsop A.E., Orsetti B.,
RA   Mozziconacci M.-J., Popovici C., Ginestier C., Letessier A.,
RA   Basset C., Courtay-Cahen C., Jacquemier J., Theillet C., Birnbaum D.,
RA   Edwards P.A.W., Chaffanet M.;
RT   "A recurrent chromosome translocation breakpoint in breast and
RT   pancreatic cancer cell lines targets the neuregulin/NRG1 gene.";
RL   Genes Chromosomes Cancer 37:333-345(2003).
//
RX   PubMed=16397213; DOI=10.1158/0008-5472.CAN-05-2853;
RA   Elstrodt F., Hollestelle A., Nagel J.H.A., Gorin M., Wasielewski M.,
RA   van den Ouweland A., Merajver S.D., Ethier S.P., Schutte M.;
RT   "BRCA1 mutation analysis of 41 human breast cancer cell lines reveals
RT   three new deleterious mutants.";
RL   Cancer Res. 66:41-45(2006).
//
RX   PubMed=16142302; DOI=10.3892/ijo.27.4.881;
RA   de Longueville F., Lacroix M., Barbuto A.-M., Bertholet V., Gallo D.,
RA   Larsimont D., Marcq L., Zammatteo N., Boffe S., Leclercq G.,
RA   Remacle J.;
RT   "Molecular characterization of breast cancer cell lines by a
RT   low-density microarray.";
RL   Int. J. Oncol. 27:881-892(2005).
//
RX   PubMed=16195238; DOI=10.1093/carcin/bgi231;
RA   Hussain-Hakimjee E.A., Peng X.-J., Mehta R.R., Mehta R.G.;
RT   "Growth inhibition of carcinogen-transformed MCF-12F breast epithelial
RT   cells and hormone-sensitive BT-474 breast cancer cells by
RT   1alpha-hydroxyvitamin D5.";
RL   Carcinogenesis 27:551-559(2006).
//
RX   PubMed=16417655; DOI=10.1186/bcr1370;
RA   Shadeo A., Lam W.L.;
RT   "Comprehensive copy number profiles of breast cancer cell model
RT   genomes.";
RL   Breast Cancer Res. 8:R9.1-R9.14(2006).
//
RX   PubMed=16541312; DOI=10.1007/s10549-006-9186-z;
RA   Wasielewski M., Elstrodt F., Klijn J.G.M., Berns E.M.J.J., Schutte M.;
RT   "Thirteen new p53 gene mutants identified among 41 human breast cancer
RT   cell lines.";
RL   Breast Cancer Res. Treat. 99:97-101(2006).
//
RX   PubMed=17157791; DOI=10.1016/j.ccr.2006.10.008;
RA   Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T.,
RA   Clark L., Bayani N., Coppe J.-P., Tong F., Speed T., Spellman P.T.,
RA   DeVries S., Lapuk A., Wang N.J., Kuo W.-L., Stilwell J.L., Pinkel D.,
RA   Albertson D.G., Waldman F.M., McCormick F., Dickson R.B.,
RA   Johnson M.D., Lippman M.E., Ethier S.P., Gazdar A.F., Gray J.W.;
RT   "A collection of breast cancer cell lines for the study of
RT   functionally distinct cancer subtypes.";
RL   Cancer Cell 10:515-527(2006).
//
RX   PubMed=17334996; DOI=10.1002/gcc.20438;
RA   Jonsson G., Staaf J., Olsson E., Heidenblad M.,
RA   Vallon-Christersson J., Osoegawa K., de Jong P.J., Oredsson S.M.,
RA   Ringner M., Hoglund M., Borg A.;
RT   "High-resolution genomic profiles of breast cancer cell lines assessed
RT   by tiling BAC array comparative genomic hybridization.";
RL   Genes Chromosomes Cancer 46:543-558(2007).
//
RX   PubMed=18386134; DOI=10.1007/s10585-008-9169-z;
RA   Hughes L., Malone C., Chumsri S., Burger A.M., McDonnell S.;
RT   "Characterisation of breast cancer cell lines and establishment of a
RT   novel isogenic subclone to study migration, invasion and
RT   tumourigenicity.";
RL   Clin. Exp. Metastasis 25:549-557(2008).
//
RX   PubMed=18516279; DOI=10.1016/j.molonc.2007.02.004;
RA   Kenny P.A., Lee G.Y., Myers C.A., Neve R.M., Semeiks J.R.,
RA   Spellman P.T., Lorenz K., Lee E.H., Barcellos-Hoff M.H.,
RA   Petersen O.W., Gray J.W., Bissell M.J.;
RT   "The morphologies of breast cancer cell lines in three-dimensional
RT   assays correlate with their profiles of gene expression.";
RL   Mol. Oncol. 1:84-96(2007).
//
RX   PubMed=19582160; DOI=10.1371/journal.pone.0006146;
RA   Kao J., Salari K., Bocanegra M., Choi Y.-L., Girard L., Gandhi J.,
RA   Kwei K.A., Hernandez-Boussard T., Wang P., Gazdar A.F., Minna J.D.,
RA   Pollack J.R.;
RT   "Molecular profiling of breast cancer cell lines defines relevant
RT   tumor models and provides a resource for cancer gene discovery.";
RL   PLoS ONE 4:E6146-E6146(2009).
//
RX   PubMed=19593635; DOI=10.1007/s10549-009-0460-8;
RA   Hollestelle A., Nagel J.H.A., Smid M., Lam S., Elstrodt F.,
RA   Wasielewski M., Ng S.S., French P.J., Peeters J.K., Rozendaal M.J.,
RA   Riaz M., Koopman D.G., ten Hagen T.L.M., de Leeuw B.H.C.G.M.,
RA   Zwarthoff E.C., Teunisse A., van der Spek P.J., Klijn J.G.M.,
RA   Dinjens W.N.M., Ethier S.P., Clevers H.C., Jochemsen A.G.,
RA   den Bakker M.A., Foekens J.A., Martens J.W.M., Schutte M.;
RT   "Distinct gene mutation profiles among luminal-type and basal-type
RT   breast cancer cell lines.";
RL   Breast Cancer Res. Treat. 121:53-64(2010).
//
RX   PubMed=19671800; DOI=10.1158/0008-5472.CAN-08-4490;
RA   Liu L., Greger J.G., Shi H., Liu Y., Greshock J., Annan R., Halsey W.,
RA   Sathe G.M., Martin A.-M., Gilmer T.M.;
RT   "Novel mechanism of lapatinib resistance in HER2-positive breast tumor
RT   cells: activation of AXL.";
RL   Cancer Res. 69:6871-6878(2009).
//
RX   PubMed=19727395; DOI=10.1371/journal.pone.0006888;
RA   Wadlow R.C., Wittner B.S., Finley S.A., Bergquist H., Upadhyay R.,
RA   Finn S.P., Loda M., Mahmood U., Ramaswamy S.;
RT   "Systems-level modeling of cancer-fibroblast interaction.";
RL   PLoS ONE 4:E6888-E6888(2009).
//
RX   PubMed=20070913; DOI=10.1186/1471-2407-10-15;
RA   Tsuji K., Kawauchi S., Saito S., Furuya T., Ikemoto K., Nakao M.,
RA   Yamamoto S., Oka M., Hirano T., Sasaki K.;
RT   "Breast cancer cell lines carry cell line-specific genomic alterations
RT   that are distinct from aberrations in breast cancer tissues:
RT   comparison of the CGH profiles between cancer cell lines and primary
RT   cancer tissues.";
RL   BMC Cancer 10:15.1-15.10(2010).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=21247443; DOI=10.1186/gb-2011-12-1-r6;
RA   Edgren H., Murumagi A., Kangaspeska S., Nicorici D., Hongisto V.,
RA   Kleivi K., Rye I.H., Nyberg S., Wolf M., Borresen-Dale A.-L.,
RA   Kallioniemi O.-P.;
RT   "Identification of fusion genes in breast cancer by paired-end
RT   RNA-sequencing.";
RL   Genome Biol. 12:R6.1-R6.13(2011).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=22585861; DOI=10.1158/2159-8290.CD-11-0224;
RA   Marcotte R., Brown K.R., Suarez Saiz F.J., Sayad A., Karamboulas K.,
RA   Krzyzanowski P.M., Sircoulomb F., Medrano M., Fedyshyn Y., Koh J.L.Y.,
RA   van Dyk D., Fedyshyn B., Luhova M., Brito G.C., Vizeacoumar F.J.,
RA   Vizeacoumar F.S., Datti A., Kasimer D., Buzina A., Mero P.,
RA   Misquitta C., Normand J., Haider M., Ketela T., Wrana J.L.,
RA   Rottapel R., Neel B.G., Moffat J.;
RT   "Essential gene profiles in breast, pancreatic, and ovarian cancer
RT   cells.";
RL   Cancer Discov. 2:172-189(2012).
//
RX   PubMed=23151021; DOI=10.1186/1471-2164-13-619;
RA   Grigoriadis A., Mackay A., Noel E., Wu P.-J., Natrajan R., Frankum J.,
RA   Reis-Filho J.S., Tutt A.;
RT   "Molecular characterisation of cell line models for triple-negative
RT   breast cancers.";
RL   BMC Genomics 13:619.1-619.14(2012).
//
RX   PubMed=23601657; DOI=10.1186/bcr3415;
RA   Riaz M., van Jaarsveld M.T.M., Hollestelle A.,
RA   Prager-van der Smissen W.J.C., Heine A.A.J., Boersma A.W.M., Liu J.-J.,
RA   Helmijr J.C.A., Ozturk B., Smid M., Wiemer E.A.C., Foekens J.A.,
RA   Martens J.W.M.;
RT   "miRNA expression profiling of 51 human breast cancer cell lines
RT   reveals subtype and driver mutation-specific miRNAs.";
RL   Breast Cancer Res. 15:R33.1-R33.17(2013).
//
RX   PubMed=23671654; DOI=10.1371/journal.pone.0063056;
RA   Lu Y.-H., Soong T.D., Elemento O.;
RT   "A novel approach for characterizing microsatellite instability in
RT   cancer cells.";
RL   PLoS ONE 8:E63056-E63056(2013).
//
RX   PubMed=24094812; DOI=10.1016/j.ccr.2013.08.020;
RA   Timmerman L.A., Holton T., Yuneva M., Louie R.J., Padro M., Daemen A.,
RA   Hu M., Chan D.A., Ethier S.P., van 't Veer L.J., Polyak K.,
RA   McCormick F., Gray J.W.;
RT   "Glutamine sensitivity analysis identifies the xCT antiporter as a
RT   common triple-negative breast tumor therapeutic target.";
RL   Cancer Cell 24:450-465(2013).
//
RX   PubMed=24162158; DOI=10.1007/s10549-013-2743-3;
RA   Prat A., Karginova O., Parker J.S., Fan C., He X.-P., Bixby L.M.,
RA   Harrell J.C., Roman E., Adamo B., Troester M.A., Perou C.M.;
RT   "Characterization of cell lines derived from breast cancers and normal
RT   mammary tissues for the study of the intrinsic molecular subtypes.";
RL   Breast Cancer Res. Treat. 142:237-255(2013).
//
RX   PubMed=24176112; DOI=10.1186/gb-2013-14-10-r110;
RA   Daemen A., Griffith O.L., Heiser L.M., Wang N.J., Enache O.M.,
RA   Sanborn Z., Pepin F., Durinck S., Korkola J.E., Griffith M., Hur J.S.,
RA   Huh N., Chung J., Cope L., Fackler M.J., Umbricht C.B., Sukumar S.,
RA   Seth P., Sukhatme V.P., Jakkula L.R., Lu Y.-L., Mills G.B., Cho R.J.,
RA   Collisson E.A., van 't Veer L.J., Spellman P.T., Gray J.W.;
RT   "Modeling precision treatment of breast cancer.";
RL   Genome Biol. 14:R110.1-R110.14(2013).
//
RX   PubMed=24389870; DOI=10.1038/srep03576;
RA   Strauch M., Ludke A., Munch D., Laudes T., Galizia C.G.,
RA   Martinelli E., Lavra L., Paolesse R., Ulivieri A., Catini A.,
RA   Capuano R., Di Natale C.;
RT   "More than apples and oranges -- detecting cancer with a fruit fly's
RT   antenna.";
RL   Sci. Rep. 4:3576-3576(2014).
//
RX   PubMed=24456987; DOI=10.1186/1755-8166-7-8;
RA   Rondon-Lagos M., Verdun Di Cantogno L., Marchio C., Rangel N.,
RA   Payan-Gomez C., Gugliotta P., Botta C., Bussolati G.,
RA   Ramirez-Clavijo S.R., Pasini B., Sapino A.;
RT   "Differences and homologies of chromosomal alterations within and
RT   between breast cancer cell lines: a clustering analysis.";
RL   Mol. Cytogenet. 7:8.1-8.14(2014).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=25892236; DOI=10.1016/j.celrep.2015.03.050;
RA   Lawrence R.T., Perez E.M., Hernandez D., Miller C.P., Haas K.M.,
RA   Irie H.Y., Lee S.-I., Blau C.A., Villen J.;
RT   "The proteomic landscape of triple-negative breast cancer.";
RL   Cell Rep. 11:630-644(2015).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
//
RX   PubMed=25984343; DOI=10.1038/sdata.2014.35;
RA   Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S.,
RA   East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H.,
RA   Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M.,
RA   Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S.,
RA   Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D.,
RA   Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C.,
RA   Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P.,
RA   Golub T.R., Root D.E., Hahn W.C.;
RT   "Parallel genome-scale loss of function screens in 216 cancer cell
RT   lines for the identification of context-specific genetic
RT   dependencies.";
RL   Sci. Data 1:140035-140035(2014).
//
RX   PubMed=26218769; DOI=10.1016/j.jchromb.2015.07.021;
RA   Willmann L., Schlimpert M., Halbach S., Erbes T., Stickeler E.,
RA   Kammerer B.;
RT   "Metabolic profiling of breast cancer: differences in central
RT   metabolism between subtypes of breast cancer cell lines.";
RL   J. Chromatogr. B 1000:95-104(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=26865974; DOI=10.1186/s13742-016-0113-x;
RA   Ciotlos S., Mao Q., Zhang R.Y., Li Z.-Y., Chin R., Gulbahce N.,
RA   Liu S.J., Drmanac R., Peters B.A.;
RT   "Whole genome sequence analysis of BT-474 using Complete Genomics'
RT   standard and long fragment read technologies.";
RL   GigaScience 5:8.1-8.17(2016).
//
RX   PubMed=27362937; DOI=10.1371/journal.pone.0157290;
RA   Carrier M., Joint M., Lutzing R., Page A., Rochette-Egly C.;
RT   "Phosphoproteome and transcriptome of RA-responsive and RA-resistant
RT   breast cancer cell lines.";
RL   PLoS ONE 11:E0157290-E0157290(2016).
//
RX   PubMed=27378269; DOI=10.1186/s12885-016-2452-5;
RA   Kangaspeska S., Hultsch S., Jaiswal A., Edgren H., Mpindi J.P.,
RA   Eldfors S., Bruck O., Aittokallio T., Kallioniemi O.-P.;
RT   "Systematic drug screening reveals specific vulnerabilities and
RT   co-resistance patterns in endocrine-resistant breast cancer.";
RL   BMC Cancer 16:378.1-378.17(2016).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=28287265; DOI=10.1021/acs.jproteome.6b00470;
RA   Yen T.-Y., Bowen S., Yen R., Piryatinska A., Macher B.A., Timpe L.C.;
RT   "Glycoproteins in claudin-low breast cancer cell lines have a unique
RT   expression profile.";
RL   J. Proteome Res. 16:1391-1400(2017).
//
RX   PubMed=28889351; DOI=10.1007/s10549-017-4496-x;
RA   Saunus J.M., Smart C.E., Kutasovic J.R., Johnston R.L.,
RA   Kalita-de Croft P., Miranda M., Rozali E.N., Vargas A.C., Reid L.E.,
RA   Lorsy E., Cocciardi S., Seidens T., McCart Reed A.E., Dalley A.J.,
RA   Wockner L.F., Johnson J., Sarkar D., Askarian-Amiri M.E.,
RA   Simpson P.T., Khanna K.K., Chenevix-Trench G., Al-Ejeh F.,
RA   Lakhani S.R.;
RT   "Multidimensional phenotyping of breast cancer cell lines to guide
RT   preclinical research.";
RL   Breast Cancer Res. Treat. 167:289-301(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=32942617; DOI=10.3390/cancers12092630;
RA   Lee H.J., Shin S., Kang J., Han K.-C., Kim Y.H., Bae J.-W., Park K.H.;
RT   "HSP90 inhibitor, 17-DMAG, alone and in combination with lapatinib
RT   attenuates acquired lapatinib-resistance in ER-positive,
RT   HER2-overexpressing breast cancer cell line.";
RL   Cancers (Basel) 12:2630.1-2630.16(2020).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//